Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a biotechnology company focusing on longevity research and age-related diseases, has released its final results for the year ending 31 December 2023. The company has received significant non-dilutive research grants from the Government of Wallonia in Belgium, completed a successful fundraise, and made strategic progress with its key research programs in MASH and Werner Syndrome. These achievements, alongside the expansion of their intellectual property portfolio and collaborations with other biotech firms, highlight Genflow’s commitment to advancing its research pipeline and financial stability.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
